Trovagene (TROV) Reports Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
Tweet Send to a Friend
Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of the second clinical trial site ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
